Panel’s Split Decision On Dyax HAE Drug Belies Consensus On Clinical Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory panel concerned with limited efficacy and safety data; members express uncertainty over standards for orphan drug approval.
You may also be interested in...
Dyax Receives “Complete Response” For HAE Drug; REMS Will Be Required
Dyax is joining a growing group of companies that have seen their approvals delayed, via a "complete response" letter, to work out a Risk Evaluation and Mitigation Strategy. The Cambridge, Mass. biotech got such a letter March 26 for ecallantide, its drug to treat acute attacks of hereditary angioedema
Dyax Receives “Complete Response” For HAE Drug; REMS Will Be Required
Dyax is joining a growing group of companies that have seen their approvals delayed, via a "complete response" letter, to work out a Risk Evaluation and Mitigation Strategy. The Cambridge, Mass. biotech got such a letter March 26 for ecallantide, its drug to treat acute attacks of hereditary angioedema
Dyax Restructures Royalty Loan Agreement, Bringing In $15 Million
Extension of royalty-sharing with Cowen Healthcare Royalty Partners enables Dyax to fund itself while awaiting FDA’s decision on ecallantide – but at a steep price.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: